{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sabei FY"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["102446"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8464505"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37"],"pubmed_abstract":["Ewing's sarcoma (EwS) is the second most common bone cancer in children and adolescents. Current chemotherapy regimens are mainly ineffective in patients with relapsed disease and cause long-term effects in survivors. Therefore, we have developed a combinatorial therapy based on a novel drug candidate named ML111 that exhibits selective activity against EwS cells and synergizes with vincristine. To increase the aqueous solubility of hydrophobic ML111, polymeric nanoparticles (ML111-NP) were developed. In vitro data revealed that ML111-NP compromise viability of EwS cells without affecting non-malignant cells. Furthermore, ML111-NP exhibit strong synergistic effects in a combination with vincristine on EwS cells, while this drug pair exhibits antagonistic effects towards normal cells. Final"],"journal":["Nanomedicine : nanotechnology, biology, and medicine"],"pubmed_title":["A targeted combinatorial therapy for Ewing's sarcoma."],"pmcid":["PMC8464505"],"funding_grant_id":["R37 CA234006","KL2 TR002370","R01 CA237569"],"pubmed_authors":["Davare MA","Leid M","Esfandiari Nazzaro E","Sabei FY","Park Y","Vogel WK","Al-Fatease AM","Demessie AA","Alani A","Albarqi HA","Moses AS","Taratula O"],"additional_accession":[]},"is_claimable":false,"name":"A targeted combinatorial therapy for Ewing's sarcoma.","description":"Ewing's sarcoma (EwS) is the second most common bone cancer in children and adolescents. Current chemotherapy regimens are mainly ineffective in patients with relapsed disease and cause long-term effects in survivors. Therefore, we have developed a combinatorial therapy based on a novel drug candidate named ML111 that exhibits selective activity against EwS cells and synergizes with vincristine. To increase the aqueous solubility of hydrophobic ML111, polymeric nanoparticles (ML111-NP) were developed. In vitro data revealed that ML111-NP compromise viability of EwS cells without affecting non-malignant cells. Furthermore, ML111-NP exhibit strong synergistic effects in a combination with vincristine on EwS cells, while this drug pair exhibits antagonistic effects towards normal cells. Final","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-31T15:56:29.08Z","creation":"2025-04-04T12:46:28.578Z"},"accession":"S-EPMC8464505","cross_references":{"pubmed":["34303840"],"doi":["10.1016/j.nano.2021.102446"]}}